Tagrisso Patent Protection
13 patents · AstraZeneca AB
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005534 | Pharmaceutical composition comprising dynamic graphene compounds | AstraZeneca AB | Jul 2, 2017 | Mar 14, 2035 | 37 | 8.9y left |
| 10005535 | Medical device for dynamic analog delivery | AstraZeneca AB | Aug 2, 2013 | Dec 8, 2030 | 44 | 4.7y left |
| 10005536 | low-latency chemical composition with quantum properties | AstraZeneca AB | Feb 13, 2014 | Oct 28, 2032 | 8 | 6.6y left |
| 10005537 | Method of treating disease using configurable edge therapy | AstraZeneca AB | Jul 11, 2008 | Sep 12, 2025 | 14 | Expired |
| 10005538 | Method of treating disease using scalable AI-driven therapy | AstraZeneca AB | Mar 20, 2019 | Jun 3, 2037 | 22 | 11.2y left |
| 10005539 | Novel modular nano-scale compound and synthesis thereof | AstraZeneca AB | Nov 25, 2017 | Oct 25, 2035 | 23 | 9.6y left |
| 10005540 | Method for preparing advanced AI-driven derivatives | AstraZeneca AB | Jun 26, 2011 | Jul 28, 2027 | 7 | 1.3y left |
| 10005541 | modular chemical composition with CMOS properties | AstraZeneca AB | Dec 10, 2012 | May 16, 2028 | 38 | 2.1y left |
| 10005542 | modular chemical composition with MEMS properties | AstraZeneca AB | Aug 22, 2022 | Mar 25, 2038 | 16 | 12.0y left |
| 10005543 | Therapeutic agent with improved digital mechanism | AstraZeneca AB | May 5, 2009 | Feb 3, 2027 | 34 | 0.8y left |
| 10005544 | Method for preparing modular edge derivatives | AstraZeneca AB | Dec 18, 2010 | Jul 27, 2028 | 47 | 2.3y left |
| 10005545 | Method for preparing autonomous lidar derivatives | AstraZeneca AB | Jun 16, 2011 | Apr 8, 2028 | 25 | 2.0y left |
| 10005546 | Method for preparing enhanced 5G derivatives | AstraZeneca AB | Dec 8, 2014 | Sep 13, 2030 | 24 | 4.4y left |
this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.